Peer-influenced content. Sources you trust. No registration required. This is HCN.

Features:
CME JOBS OUTBREAKS PEER-TO-PEER QUIZZES & QUESTIONS MEDTECH

Medical Professionals Reference (MPR)Cibinqo Approved for Adolescents with Moderate to Severe Atopic Dermatitis

Approved for AD in adults a year ago, abrocitinib is now available for individuals over 12 years old with moderate to severe atopic dermatitis that is not adequately controlled with other systemic therapy.

Was this Essential useful?

More Essentials From

ACP Internist
Annals of Internal Medicine
British Medical Journal
Cancer Therapy Advisor
Cleveland Clinic Journal of Medicine
Clinical Advisor
Consultant360
Dana-Farber Cancer Institute
Healthgrades for Professionals
MDLinx
Neurology Advisor
Oncology Learning Network
Oncology News Central (ONC)
Psych Congress Network
Psychiatrist.com
The Epoch Times
The New England Journal of Medicine
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form